Alpha 2.0
Login Register
» Authors » Eleni Karamouza

Eleni Karamouza

Explore the profile of Eleni Karamouza including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 85
Followers 0
Related Specialties
Oncology
General Medicine
Top 10 Co-Authors
Nozomu Yanaihara
Xavier Paoletti
Liz-Anne Lewsley
Rosalind M Glasspool
Tatsuo Kagimura
Benoit You
Eric Pujade-Lauraine
Adrian Cook
Stephen Welch
Ingrid A Boere
Published In
Clin Cancer Res
Cancers (Basel)
JAMA Oncol
Eur J Cancer
JAMA Netw Open
Affiliations
Soon will be listed here.
Recent Articles
1.
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis
Corbaux P, You B, Glasspool R, Yanaihara N, Tinker A, Lindemann K, et al.
Eur J Cancer . 2023 Aug; 191:112966. PMID: 37542936
Background: In patients with advanced ovarian cancer, the modelled CA-125 ELIMination rate constant K (KELIM) is an early indicator of the tumour intrinsic chemosensitivity. We assessed the prognostic and surrogate...
2.
CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data
Karamouza E, Glasspool R, Kelly C, Lewsley L, Carty K, Kristensen G, et al.
Cancers (Basel) . 2023 Mar; 15(6). PMID: 36980708
(1) Background: Cancer antigen 125 (CA-125) is a protein produced by ovarian cancer cells that is used for patients' monitoring. However, the best ways to analyze its decline and prognostic...
3.
Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis
Paoletti X, Lewsley L, Daniele G, Cook A, Yanaihara N, Tinker A, et al.
JAMA Netw Open . 2020 Jan; 3(1):e1918939. PMID: 31922558
Importance: The Gynecologic Cancer InterGroup (GCIG) recommended that progression-free survival (PFS) can serve as a primary end point instead of overall survival (OS) in advanced ovarian cancer. Evidence is lacking...
4.
Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials
Terrisse S, Karamouza E, Parker C, Sartor A, James N, Pirrie S, et al.
JAMA Oncol . 2019 Dec; 6(2):206-216. PMID: 31830233
Importance: Both α-emitting and β-emitting bone-targeted radioisotopes (RIs) have been developed to treat men with metastatic castration-resistant prostate cancer (CRPC). Only 1 phase 3 randomized clinical trial has demonstrated an...
5.
Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation?
Enrico D, Paci A, Chaput N, Karamouza E, Besse B
Clin Cancer Res . 2019 Nov; 26(4):787-792. PMID: 31757876
The generation of antibodies following exposure to therapeutic drugs has been widely studied, however in oncology, data in relation to their clinical relevance are limited. Antidrug antibodies (ADAs) can cause...